Infinity Announces First Quarter 2009 Results Conference Call
April 28, 2009 10:00 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 28, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that Infinity management...
Infinity Presents New Preclinical Data From Its Heat Shock Protein 90 Inhibitor Program At AACR
April 21, 2009 15:00 ET
|
Infinity Pharmaceuticals, Inc.
DENVER, Colo. and CAMBRIDGE, Mass., April 21, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today presented data from its heat shock protein 90 (Hsp90) inhibitor program that...
Infinity Presents Preclinical Data Demonstrating Potential of Hedgehog Pathway Inhibition With IPI-926 in Multiple Cancer Settings
April 21, 2009 10:00 ET
|
Infinity Pharmaceuticals, Inc.
DENVER and CAMBRIDGE, Mass., April 21, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today presented preclinical data from studies of IPI-926, its oral Hedgehog pathway...
Infinity Halts RING Trial in Advanced Gastrointestinal Stromal Tumors
April 15, 2009 09:15 ET
|
Infinity Pharmaceuticals, Inc.
-- Decision Based On Recommendation Received Tuesday Night From
Independent Data Monitoring Committee --
-- Infinity Reaffirms Commitment to Hsp90 Development and Cash
...
Infinity to Present Preclinical Data From Its Hsp90 Inhibitor Program and Its Hedgehog Signaling Pathway Inhibitor Program At AACR Meeting
April 08, 2009 06:30 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 8, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that it will be reporting...
Infinity Announces Leadership Promotions
April 07, 2009 06:30 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 7, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced two leadership...
Infinity Initiates International Phase 2 Trial of IPI-504 in Combination With Herceptin(r) in Patients With HER2-Positive Breast Cancer
March 30, 2009 06:30 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., March 30, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced the initiation of a...
Infinity Presents the Chemistry and Discovery of IPI-926, Its Novel Hedgehog Signaling Pathway Inhibitor, At ACS Meeting
March 25, 2009 11:00 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass. and SALT LAKE CITY, March 25, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced data...
Infinity to Present At the Future Leaders Conference
March 23, 2009 07:30 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., March 23, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that Steven H. Holtzman,...
Infinity to Present the Discovery of IPI-926, Its Hedgehog Signaling Pathway Inhibitor, At ACS Meeting
March 17, 2009 07:30 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., March 17, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that it will be...